First Line Ovarian Cancer Treatment - Cohort Study

NCT01832415 · clinicaltrials.gov ↗

COMPLETED

Status

500

Enrollment

OTHER

Sponsor class

Conditions

Epithelial Ovarian Cancer

Interventions

DRUG: Bevacizumab

Sponsor

ARCAGY/ GINECO GROUP

Collaborators

[object Object]